🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to scientists.

A Worldwide Public Health Issue

Cases of gonorrhoea are on the rise worldwide, with estimates suggesting in excess of 82 million new cases annually. Notably increased rates are observed in the African continent and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary development in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices currently available.”

Medical experts are deeply concerned about the increase in antibiotic-resistant strains. The World Health Organization has listed it as a "critical concern". A tracking program found that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Receive Approval

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in mid-December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Scientists hope that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GSK, gained clearance in concurrent days. This medication, which is employed against urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment stemmed from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the drug firm its industry partner to bring it to fruition.

“This approval represents a huge turning point in the treatment of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Results and Global Access

As per data detailed in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the current standard treatment, which combines an injection and a pill. The study involved hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the authority to make available and distribute the drug in numerous regions with limited resources.

Clinicians treating patients have shared hope. Access to a easy-to-administer therapy such as this is hailed as a "revolutionary step" for managing the epidemic. This is viewed as crucial to lessen the impact of the illness for patients and to prevent the spread of untreatable gonorrhoea worldwide.